Athira Pharma Inc
ATHA
Get informed when a big investor buys or sells
+ FollowMarket Cap$160.15M
Close$
$12.27
81.8% upside
Current Fair Value
81.8% upsideUndervalued by 81.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $160.15 Million |
|---|---|
| Enterprise Value | $128.41 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-24.7 |
| Beta | 2.8 |
| Outstanding Shares | 23,726,211 |
Return
| Return on Equity | -421.06% |
|---|---|
| Return on Assets | -248.63% |
| Return on Invested Capital | -250.80% |
Valuation & Multiples
| P/E Ratio | -0.18 |
|---|---|
| PEG | -0.1 |
| Price to Sales | - |
| Price to Book Ratio | 6.75 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.04 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | -0.11 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 32.61%▲ 23.60% |
|---|---|
| Total Invested | $46.70M▲ 512.59% |
| Investors Holding | 42▲ 9.00% |
ESG Score
No data
About Athira Pharma Inc
19 employees
CEO: Mark J. Litton LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of ne...